Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Protagonist Therapeutics Inc
PTGXCurrent price
41.11 USD
-0.06 USD (-0.15%)
Last closed
41.04 USD
Company
www.protagonist-inc.com
ISIN
US74366E1029
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 755 215 616 USD
Yield for 12 month
+144.56 %
1Y
3Y
5Y
10Y
15Y
PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
54.86 USDP/E ratio
16.8723Dividend Yield
–Current Year
+60 000 000 USD
Last Year
+26 581 000 USD
Current Quarter
+4 675 000 USD
Last Quarter
+4 167 000 USD
Current Year
+56 688 000 USD
Last Year
+26 581 000 USD
Current Quarter
+4 675 000 USD
Last Quarter
+3 275 000 USD
Key Figures PTGX
1 year
3 years
5 years
10 years
EBITDA
150 068 000 USD
Operating Margin TTM
PE Ratio
16.8723
Return On Assets TTM
19.96 %
PEG Ratio
–
Return On Equity TTM
40.97 %
Wall Street Target Price
54.86 USD
Revenue TTM
323 795 008 USD
Book Value
8.94 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
26 581 000 USD
Earnings per share
2.74 USD
Diluted Eps TTM
2.74 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
52.77 %
Dividend Analytics PTGX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PTGX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PTGX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
16.8723
Forward PE
41.3223
Enterprise Value Revenue
7.0952
Price Sales TTM
8.5091
Enterprise Value EBITDA
15.0844
Price Book MRQ
5.1798
Financials PTGX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PTGX
For 52 weeks
15.58 USD
48.89 USD
50 Day MA
45.54 USD
Shares Short Prior Month
3 520 031
200 Day MA
35.08 USD
Short Ratio
4.19
Shares Short
3 001 498
Short Percent
5.17 %
BeatStart